Other Information
+Added: During the quarter ended September 30, 2023, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted, terminated or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K).
The exhibits listed below are filed or furnished as part of this report.
+Added: Table of Content
Number Description
15 unchanged sentences
The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.
−Removed: Table o f Content
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Somerset, State of New Jersey.
−Removed: Aquestive Therapeutics, Inc.
−Removed: August 7, 2023 /s/ Daniel Barber
−Removed: Daniel Barber
−Removed: President and Chief Executive Officer
−Removed: (Principal Executive Officer)
−Removed: August 7, 2023 /s/ A.
−Removed: Ernest Toth, Jr.
−Removed: Ernest Toth, Jr.
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.